Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in advanced esophagogastric cancers in a phase 1/2 trial.
Authors
David James Pinato
Imperial College, London, United Kingdom
David James Pinato , Robert Hugh Jones , Martin D. Forster , Anthony M. Joshua , James Korolewicz , Sarah Benafif , Karam Aboud , Jia (Jenny) Liu , Rasha Cosman , Jeremy Paull , Jacinth Fairley , Stephanie Ruth Edmondson , James F. Spicer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
EudraCT 2017-003424-76
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 374)
DOI
10.1200/JCO.2024.42.3_suppl.374
Abstract #
374
Poster Bd #
H16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of SY-3505, a third-generation ALK TKI, in ALK-positive advanced non-small cell lung cancer: Results from a phase I/II, multi-center study.
First Author: Yuankai Shi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The overall safety and short-term efficacy of nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma.
First Author: Kazuhiro Shiraishi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan.
First Author: Kunihiro Fushiki
Poster
2023 ASCO Breakthrough
Efficacy and safety of pembrolizumab in advanced neuroendocrine tumors (NETs): A meta-analysis of clinical trials.
First Author: Akshit Chitkara